Evidence map›Paper›PMID 25175337›Full record

ReviewProgress in biophysics and molecular biology

NMR approaches in structure-based lead discovery: recent developments and new frontiers for targeting multi-protein complexes.

David M Dias, Alessio Ciulli

Abstract readReview
In one paragraph

Review in Progress in biophysics and molecular biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Review
  2. How does NMR support SARS-CoV-2 protein-ligand interaction studies?Analytical and bioanalytical chemistry · 2026
    Review
  3. Target Engagement Assays in Early Drug Discovery.Journal of medicinal chemistry · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. A Two-Armed Probe for In-Cell DEER Measurements on Proteins*.Chemistry (Weinheim an der Bergstrasse, Germany) · 2020
    Article
  13. NMR in target driven drug discovery: why not?Journal of biomolecular NMR · 2020
    Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Spy vs. spy: selecting the best reporter forChemical communications (Cambridge, England) · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

David M DiasDepartment of Chemistry, University of Cambridge, Cambridge, CB2 1EW, UK.
Alessio CiulliCollege of Life Sciences, Division of Biological Chemistry and Drug Discovery, University of Dundee, Dow Street, DD1 5EH, Dundee, UK. Electronic address: a.ciulli@dundee.ac.uk.

Funding

Biotechnology and Biological Sciences Research Council BB/G023123/1Biotechnology and Biological Sciences Research Council BB/J001201/1European Research Council 311460
6 · The paper itself

Abstract

Nuclear magnetic resonance (NMR) spectroscopy is a pivotal method for structure-based and fragment-based lead discovery because it is one of the most robust techniques to provide information on protein structure, dynamics and interaction at an atomic level in solution. Nowadays, in most ligand screening cascades, NMR-based methods are applied to identify and structurally validate small molecule binding. These can be high-throughput and are often used synergistically with other biophysical assays. Here, we describe current state-of-the-art in the portfolio of available NMR-based experiments that are used to aid early-stage lead discovery. We then focus on multi-protein complexes as targets and how NMR spectroscopy allows studying of interactions within the high molecular weight assemblies that make up a vast fraction of the yet untargeted proteome. Finally, we give our perspective on how currently available methods could build an improved strategy for drug discovery against such challenging targets.

Indexed as

Drug DiscoveryLigandsMagnetic Resonance SpectroscopyProteinsLigandsProteinsHit-to-lead optimizationMulti-protein complexesNMR fragment screeningProtein expressionProtein–protein interactionsStructure-based lead discovery

Identifiers

PMID25175337
PMCPMC4261069

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.